Clinical trial
A Phase 2b/3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABBV-2294 (Combination of ABBV-722 and Upadacitinib) in Adult Patients With Systemic Sclerosis
NCT07933211 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b/3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABBV-2294 (Combination of ABBV-722 and Upadacitinib) in Adult Patients With Systemic Sclerosis
- Lead sponsor
- AbbVie
- Phase
- Phase 2/3
- Overall status
- Not yet recruiting
- Start date
- December 11, 2026
- Completion date
- June 30, 2035
- Enrollment
- 580 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
systemic sclerosis
Arms
As registered; 5 arms.
-
Part 1: Double Blind Placebo Controlled Arm 1
Participants are randomized to receive Dose 1: ABBV-2294 (combination of ABBV-722 and upadacitinib)
-
Part 1: Double Blind Placebo Controlled Arm 2
Participants are randomized to receive Dose 2: ABBV-2294 (combination of ABBV-722 and upadacitinib)
-
Part 1: Double Blind Placebo Controlled Arm 3
Participants are randomized to receive ABBV-722
-
Part 1: Double Blind Placebo Controlled Arm 4
Participants are randomized to receive upadacitinib
-
Part 1: Double Blind Placebo Controlled Arm 5
Participants are randomized to receive placebo
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Part 1 & Part 2: Achievement of Revised Composite Response Index in Systemic Sclerosis (rCRISS)-25
The rCRISS is a 2-step process wherein participants are determined to be considered as a responder or a non-responder. The first step of the rCRISS accounts for worsening or incident cases of any internal organ involvement. If the participant meets any of the Step 1 criteria, they are considered a non-responder in the trial afterwards. Step 2 includes 5 core set measures. The FVC% is evaluated to see if the change is at least 5%. The other 4 core set measures (modified Rodnan skin score (mRSS), Health Assessment Questionnaire Disability Index (HAQ-DI), Patient Global Assessment (PGA) and clinician global assessment) are evaluated for change of at least 25%. A responder is a participant who has relative improvement on at least 2 of the 5 core set measures without worsening on more than 1 core set measure
-
Part 1 & Part 2: Number of Participants Experiencing Adverse Events
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Lead sponsor's other trials
AbbVie, most recent start first.
+1,194 more trials See the organization page
Similar trials
Same condition (Scleroderma, Systemic) and phase, most recent start first.
+10 more trials See the condition page